Veeva Systems (NYSE:VEEV) Updates FY25 Earnings Guidance

Veeva Systems (NYSE:VEEV) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $6.22 for the period, compared to the consensus earnings per share estimate of $6.16. The company issued revenue guidance of $2.704-2.710 billion, compared to the consensus revenue estimate of $2.71 billion. Veeva Systems also updated its FY 2025 guidance to 6.220-6.220 EPS.

Veeva Systems Stock Performance

NYSE:VEEV opened at $217.00 on Friday. Veeva Systems has a 52 week low of $162.72 and a 52 week high of $236.90. The firm’s fifty day moving average is $187.82 and its 200-day moving average is $202.03. The firm has a market cap of $35.08 billion, a P/E ratio of 64.01, a P/E/G ratio of 1.95 and a beta of 0.80.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Wednesday, August 28th. The technology company reported $1.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.04 by $0.03. The firm had revenue of $676.18 million during the quarter, compared to the consensus estimate of $667.21 million. Veeva Systems had a return on equity of 12.74% and a net margin of 22.34%. As a group, sell-side analysts anticipate that Veeva Systems will post 4.19 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on VEEV shares. Robert W. Baird boosted their target price on shares of Veeva Systems from $245.00 to $251.00 and gave the company an outperform rating in a research report on Thursday. Piper Sandler boosted their target price on Veeva Systems from $225.00 to $230.00 and gave the company an overweight rating in a research report on Thursday. Evercore ISI cut their price target on Veeva Systems from $230.00 to $200.00 and set an in-line rating on the stock in a report on Friday, May 31st. Canaccord Genuity Group decreased their price objective on Veeva Systems from $220.00 to $210.00 and set a hold rating for the company in a report on Friday, May 31st. Finally, UBS Group increased their target price on Veeva Systems from $185.00 to $215.00 and gave the stock a neutral rating in a report on Monday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Veeva Systems currently has a consensus rating of Moderate Buy and an average target price of $230.13.

Insiders Place Their Bets

In related news, SVP Jonathan Faddis sold 2,353 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $200.00, for a total value of $470,600.00. Following the transaction, the senior vice president now owns 9,035 shares in the company, valued at $1,807,000. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CFO Timothy S. Cabral sold 15,000 shares of Veeva Systems stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $184.33, for a total value of $2,764,950.00. Following the completion of the transaction, the chief financial officer now owns 8,391 shares in the company, valued at $1,546,713.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jonathan Faddis sold 2,353 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $200.00, for a total transaction of $470,600.00. Following the sale, the senior vice president now owns 9,035 shares in the company, valued at $1,807,000. The disclosure for this sale can be found here. Insiders own 10.50% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.